NAGE vs. ACLX, ALVO, ZLAB, RARE, VKTX, CPRX, MTSR, MOR, PTGX, and CRNX
Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Arcellx (ACLX), Alvotech (ALVO), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Metsera (MTSR), MorphoSys (MOR), Protagonist Therapeutics (PTGX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Niagen Bioscience vs.
Arcellx (NASDAQ:ACLX) and Niagen Bioscience (NASDAQ:NAGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
Arcellx has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Arcellx received 68 more outperform votes than Niagen Bioscience when rated by MarketBeat users. However, 100.00% of users gave Niagen Bioscience an outperform vote while only 83.13% of users gave Arcellx an outperform vote.
In the previous week, Niagen Bioscience had 2 more articles in the media than Arcellx. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Arcellx. Arcellx's average media sentiment score of 1.75 beat Niagen Bioscience's score of 0.57 indicating that Arcellx is being referred to more favorably in the media.
Niagen Bioscience has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Niagen Bioscience's return on equity of 0.00% beat Arcellx's return on equity.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 8.4% of Arcellx shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Arcellx currently has a consensus price target of $111.33, suggesting a potential upside of 66.57%. Niagen Bioscience has a consensus price target of $13.00, suggesting a potential upside of 10.26%. Given Arcellx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcellx is more favorable than Niagen Bioscience.
Niagen Bioscience has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Niagen Bioscience beats Arcellx on 11 of the 19 factors compared between the two stocks.
Get Niagen Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Niagen Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:NAGE) was last updated on 6/4/2025 by MarketBeat.com Staff
